NASDAQ: NARIInari Medical Inc Stock
$38.70-0.40 (-1.02%)
Updated Apr 17, 2024
NARI Price
$38.70
Fair Value Price
-$37.54
Market Cap
$2.24B
52 Week Low
$38.35
52 Week High
$71.85
P/E
-1,290x
P/B
4.82x
P/S
7.47x
PEG
N/A
Dividend Yield
N/A
Revenue
$493.63M
Earnings
-$1.64M
Gross Margin
88%
Operating Margin
0.9%
Profit Margin
-0.3%
Debt to Equity
0.45
Operating Cash Flow
$36M
Beta
1.31
Next Earnings
May 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A
NARI Overview
Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore suture retention device designed to address various aspects of venous access site; and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NARI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NARI ($38.70) is overvalued by 203.09% relative to our estimate of its Fair Value price of -$37.54 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NARI ($38.70) is not significantly undervalued (203.09%) relative to our estimate of its Fair Value price of -$37.54 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NARI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NARI due diligence checks available for Premium users.
Be the first to know about important NARI news, forecast changes, insider trades & much more!
NARI News
Valuation
NARI fair value
Fair Value of NARI stock based on Discounted Cash Flow (DCF)
Price
$38.70
Fair Value
-$37.54
Undervalued by
203.09%
NARI ($38.70) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NARI ($38.70) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NARI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NARI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1,290x
Industry
28.84x
Market
41.64x
NARI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.82x
Industry
3.66x
NARI is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NARI's financial health
Profit margin
Revenue
$132.1M
Net Income
-$4.7M
Profit Margin
-3.5%
NARI's Earnings (EBIT) of $4.44M... subscribe to Premium to read more.
Interest Coverage Financials
NARI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$674.2M
Liabilities
$209.3M
Debt to equity
0.45
NARI's short-term assets ($235.56M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NARI's short-term assets ($235.56M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NARI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NARI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$12.2M
Investing
-$59.7M
Financing
-$2.4M
NARI's operating cash flow ($35.93M)... subscribe to Premium to read more.
Debt Coverage Financials
NARI vs Medical Device Stocks
Inari Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.